Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04499950
Other study ID # IRB00223131
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date February 8, 2021
Est. completion date December 31, 2026

Study information

Verified date February 2024
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single arm phase II study designed to determine the effects of pharmacotherapy and a remote behavioral weight loss intervention on weight loss in breast cancer survivors who are overweight or obese, and the impact of successful weight loss on serum biomarkers and gut microbiome.


Description:

The investigators will evaluate the extent to which implementation of a chronic weight loss medication, Contrave® (Naltrexone/Bupropion), is associated with achieving ≥5% weight loss. All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose ≥5%, designated fast responders, will continue with BWL alone (FAST-BWL) while those who lose <5%, designated slow responders, will continue BWL and initiate Contrave (SLOW-BWL). The SLOW-BWL arm will receive at least 16 weeks of Contrave (as per Federal Drug Administration [FDA] recommended administration) starting at week 9 and discontinue if ≥5% weight loss is not achieved at month 6. During month 3, all participants continue to have weekly calls with the behavioral coach and will be asked about symptoms, which may be related to initiation of pharmacotherapy; any symptoms are reported to the PI for further evaluation. In addition to total weight loss, the investigators will evaluate biomarkers associated with obesity, microbiome and cardiometabolic factors.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 55
Est. completion date December 31, 2026
Est. primary completion date January 10, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female, at least 3 months after completion of local therapy (e.g. surgery, radiation), and if applicable, adjuvant chemotherapy - Diagnosed within 10 years with histologically-confirmed ductal carcinoma in situ (DCIS) or stage I-III invasive carcinoma of the breast - Up to date with recommended screening mammography within one year - Current BMI = 30 kg/m2 or BMI 27.0-29.9 kg/m2 with hypertension, non-insulin dependent diabetes or hyperlipidemia; and weight = 400 lbs - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Willingness to change diet, physical activity, track behaviors, engage in weekly and monthly contacts and visit, and take chronic weight loss medication - Able to read and write the English language without assistance and daily access to the e-mail and/or smartphone - Patient is aware of her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form. Exclusion Criteria: - Serious/uncontrolled medical condition at the discretion of the Protocol Chair/designee likely to hinder accurate measurement of weight or any condition for which weight loss is contraindicated or would affect adipokine and inflammatory markers (e.g. active malignancy, end stage renal disease on dialysis, cirrhosis, autoimmune disease, adrenal disease, uncontrolled hypertension, seizure disorder, and history of bariatric surgery) - Pregnant or nursing within past 6 months, or plans to become pregnant in the next year - Currently enrolled or planning to enroll in a weight loss program (e.g. Weight Watchers, Jenny Craig, Nutrisystem and Medifast) or to take a chronic weight loss medication. - Diabetes on insulin or sulfonylureas within the past 3 months - Unstable psychiatric disorder or bulimia/anorexia nervosa - Alcohol, nicotine or substance abuse; or undergoing abrupt discontinuation of alcohol, benzodiazepine, barbiturate or anti-epileptic drug - Use of the following medications are excluded: - Monoamine oxidase (MAO) inhibitors (must be >14 days from discontinuation) - Thyroid medication use unless on stable doses for at least the past 3 months - Buproprion containing products or opiate agonists (must be >14 days from discontinuation) - Medications that cause weight loss (e.g., lorcaserin, phentermine, orlistat, Qsymia, Contrave) within the past 3 months - Medications that are likely to cause weight gain or prevent weight loss (e.g., corticosteroids, lithium, olanzapine, risperidone, clozapine, oral contraceptive pills, hormone replacement therapy) within the past 3 months. NOTE: An exception to this is that SSRI's and SNRI's are allowed if participant has been on stable doses for at least 3 months (if discontinued, a washout of 2 weeks from prior selective serotonin reuptake inhibitor (SSRI)/Serotonin-norepinephrine reuptake inhibitor (SNRI) use is required). - Medications that may affect adipokine or inflammatory markers (e.g., metformin, glitazones, steroids, angiotensin converting enzyme (ACE) inhibitors, beta blockers and statins) unless on stable doses =3 months prior to registration (if discontinued, a washout of 2 weeks from prior use is required). Concurrent NSAIDs are allowed if use is limited to <3 times per week; chronic NSAIDs are permitted on study only if use has been =3 times per week for at least 3 months prior to registration and is expected to continue.

Study Design


Intervention

Drug:
Contrave
Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.
Behavioral:
Behavioral Weight Loss
6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.

Locations

Country Name City State
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland

Sponsors (4)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Institute for Cancer Research, Breast Cancer Research Foundation, Hopkins-WellSpan Cancer Research Fund

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of patients with 5% weight loss (in FAST-BWL) To assess the proportion of women in the FAST-BWL arm who maintain =5% weight loss at 6 months. 6 months
Other Number of participants with AA genotype and 5% weight loss To assess prevalence of AA genotype of MnSOD in breast cancer survivors with excess weight and if a greater proportion of women with the AA genotype achieve =5% weight loss and improvement in biomarkers at 6 months compared to the women who do not. 6 months
Other Number of participants with AA genotype and Contrave To determine if women who display the AA genotype of MnSOD and undergo addition of Contrave to BWL have greater weight loss compared to women who do not receive Contrave. 6 months
Primary Number of patients with 5 percent weight loss (in SLOW-BWL) To assess the rate of SLOW-BWL patients attaining at least 5% weight loss of their baseline body weight at 6 months with the addition of Contrave to BWL at week 9. 6 months
Secondary Change in HbA1c levels among SLOW-BWL participants who achieve =5% weight loss To compare HbA1c (%) levels at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in HbA1c levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare HbA1c (%) levels at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in HbA1c levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare HbA1c (%) levels at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in IGF1 levels among SLOW-BWL participants who achieve =5% weight loss To compare Insulin-like growth factor 1 (IGF1) (ng/mL) levels at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in IGF1 levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare IGF1 (ng/mL) levels at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss Baseline, 2 months and 6 Months
Secondary Change in IGF1 levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare IGF1 (ng/mL) levels at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Fasting glucose levels among SLOW-BWL participants who achieve =5% weight loss To compare fasting glucose (mg/dL) levels at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Fasting glucose levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare fasting glucose (mg/dL) levels at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Fasting glucose levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare fasting glucose (mg/dL) levels at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Fasting lipids levels among SLOW-BWL participants who achieve =5% weight loss To compare fasting lipids (mg/dL) levels at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Fasting lipids levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare fasting lipids (mg/dL) levels at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Fasting lipids levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare fasting lipids (mg/dL) levels at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. 6 Months
Secondary Change in Fasting insulin levels among SLOW-BWL participants who achieve =5% weight loss To compare fasting insulin (mIU/L) levels at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Fasting insulin levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare fasting insulin (mIU/L) levels at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Fasting insulin levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare fasting insulin (mIU/L) levels at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Adiponectin levels among SLOW-BWL women who achieve =5% weight loss To compare adiponectin (ng/mL) levels at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Adiponectin levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare adiponectin (ng/mL) levels at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Adiponectin levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare adiponectin (ng/mL) levels at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Leptin levels among SLOW-BWL participants who achieve =5% weight loss To compare leptin (ng/mL) levels at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Leptin levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare leptin (ng/mL) levels at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Leptin levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare leptin (ng/mL) levels at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to Baseline, 2 months and 6 Months
Secondary Change in Microbiome composition among SLOW-BWL participants who achieve =5% weight loss To compare microbiome composition (ratio of bacteroides and firmacutes) at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Microbiome composition among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare microbiome composition (ratio of bacteroides and firmacutes) at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Microbiome composition among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare microbiome composition (ratio of bacteroides and firmacutes) at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on Godin Leisure-Time Exercise questionnaire among SLOW-BWL participants who achieve =5% weight loss To compare Godin (score range start from 0 with no upper limit but higher scores indicate more exercise) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on Godin Leisure-Time Exercise questionnaire among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare Godin (score range start from 0 with no upper limit but higher scores indicate more exercise) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on Godin Leisure-Time Exercise questionnaire among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare Godin (score range start from 0 with no upper limit but higher scores indicate more exercise) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on Pittsburgh Sleep Quality Index (PSQI) questionnaire among SLOW-BWL participants who achieve =5% weight loss To compare PSQI (scores range 0-21 with higher scores indicating poorer sleep) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on Pittsburgh Sleep Quality Index (PSQI) questionnaire among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare PSQI (scores range 0-21 with higher scores indicating poorer sleep) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on Pittsburgh Sleep Quality Index (PSQI) questionnaire among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare PSQI (scores range 0-21 with higher scores indicating poorer sleep) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function - Short Form questionnaire among SLOW-BWL participants who achieve =5% weight loss To compare Physical Function - Short Form (scores range 10-50 with higher scores indicating better physical functioning) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Physical Function - Short Form questionnaire among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare Physical Function - Short Form (scores range 10-50 with higher scores indicating better physical functioning) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Physical Function - Short Form questionnaire among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare Physical Function - Short Form (scores range 10-50 with higher scores indicating better physical functioning) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Pain Interference - Short Form questionnaire among SLOW-BWL participants who achieve =5% weight loss To compare Pain Interference - Short Form (scores range 6-30 with lower scores indicating less pain interference) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Pain Interference - Short Form questionnaire among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare Pain Interference - Short Form (scores range 6-30 with lower scores indicating less pain interference) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Pain Interference - Short Form questionnaire among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare Pain Interference - Short Form (scores range 6-30 with lower scores indicating less pain interference) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Fatigue - Short Form questionnaire among SLOW-BWL participants who achieve =5% weight loss To compare Fatigue - Short Form (scores range 7-35 with higher scores indicating more fatigue) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Fatigue - Short Form questionnaire among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare Fatigue - Short Form (scores range 7-35 with higher scores indicating more fatigue) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Fatigue - Short Form questionnaire among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare Fatigue - Short Form (scores range 7-35 with higher scores indicating more fatigue) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Emotional Distress - Depression - Short Form questionnaire among SLOW-BWL participants who achieve =5% weight loss To compare Depression - Short Form (scores range 8-40 with lower scores indicating lower levels of depression) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Emotional Distress - Depression - Short Form questionnaire among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare Depression - Short Form (scores range 8-40 with lower scores indicating lower levels of depression) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Emotional Distress - Depression - Short Form questionnaire among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare Depression - Short Form (scores range 8-40 with lower scores indicating lower levels of depression) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Emotional Distress - Anxiety - Short Form questionnaire among SLOW-BWL participants who achieve =5% weight loss To compare Anxiety - Short Form (scores range 7-35 with lower scores indicating lower levels of anxiety) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Emotional Distress - Anxiety - Short Form questionnaire among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare Anxiety - Short Form (scores range 7-35 with lower scores indicating lower levels of anxiety) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on PROMIS Emotional Distress - Anxiety - Short Form questionnaire among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare Anxiety - Short Form (scores range 7-35 with lower scores indicating lower levels of anxiety) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on Sexual Function questionnaire among SLOW-BWL participants who achieve =5% weight loss To compare Sexual Function (scores range 4-20 with lower scores indicating better sexual functioning) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on Sexual Function questionnaire among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare Sexual Function (scores range 4-20 with lower scores indicating better sexual functioning) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on Sexual Function questionnaire among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare Sexual Function (scores range 4-20 with lower scores indicating better sexual functioning) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in NCI quick food scan comparison among SLOW-BWL participants who achieve =5% weight loss To compare NCI quick food scan scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in NCI quick food scan comparison among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare NCI quick food scan scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in NCI quick food scan comparison among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare NCI quick food scan scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Scores on Functional Assessment of Cancer Therapy-Endocrine Subscale (FACT-ES) among SLOW-BWL participants who achieve =5% weight loss To compare FACT-ES (scores range 0-76 with higher scores indicating poorer functional assessment) scores at 2 and 6 months to baseline levels among SLOW-BWL who achieve =5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on Functional Assessment of Cancer Therapy-Endocrine Subscale (FACT-ES) among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss To compare FACT-ES (scores range 0-76 with higher scores indicating poorer functional assessment) scores at 2 and 6 months to baseline levels among SLOW-BWL women who achieve =5% weight loss versus the SLOW-BWL women who do not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Scores on Functional Assessment of Cancer Therapy-Endocrine Subscale (FACT-ES) among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to To compare FACT-ES (scores range 0-76 with higher scores indicating poorer functional assessment) scores at 2 and 6 months to baseline levels among FAST-BWL vs SLOW-BWL, as well as participants who achieve =5% weight loss at 6 months vs those who are unable to. Baseline, 2 months and 6 Months
Secondary Change in Minutes of Moderate to Vigorous Physical Activity (MVPA) To compare minutes of MVPA reported in Fitbit at 2 and 6 months to baseline levels among SLOW-BWL who achieved =5% weight loss vs the SLOW-BWL who did not achieve 5% weight loss. Baseline, 2 months and 6 Months
Secondary Change in Number of daily steps To compare the number of daily steps reported in Fitbit at 2 and 6 months to baseline levels among SLOW-BWL who achieved =5% weight loss vs the SLOW-BWL who did not achieve 5% weight loss. Baseline, 2 months and 6 Months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A